Remy Bernarda | Investor Relations |
Adam Craig | President, Chief Executive Officer and Interim Chief Medical Officer |
David Kirske | Chief Financial Officer |
Jim Fong | Chief Commercial Officer |
Ken Shields | SVB Securities |
Ben Burnett | Stifel |
Gil Blum | Needham |
Reni Benjamin | JMP Securities |
Thomas Flaten | Lake Street Capital Markets |
Robert Hazlett | BTIG |
Good morning, and welcome to the CTI BioPharma Fourth Quarter and Year-End 2022 Financial Results and Corporate Update Conference Call.
As a reminder, this conference call is being recorded.
I would now like to introduce your host, Remy Bernarda, CTI Investor Relations. Please go ahead.
Good morning, everyone, and thank you for joining us on the call today.